Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules, including various cytokines or chemokines. Here, we have deve...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Ther Oncolytics
Glavni autori: Ylösmäki, Erkko, Ylösmäki, Leena, Fusciello, Manlio, Martins, Beatriz, Ahokas, Petra, Cojoc, Hanne, Uoti, Arttu, Feola, Sara, Kreutzman, Anna, Ranki, Tuuli, Karbach, Julia, Viitala, Tapani, Priha, Petri, Jäger, Elke, Pesonen, Sari, Cerullo, Vincenzo
Format: Artigo
Jezik:Inglês
Izdano: American Society of Gene & Cell Therapy 2021
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917457/
https://ncbi.nlm.nih.gov/pubmed/33718594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2021.02.006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items